<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30819267</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">0317-1671</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>46</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques</Title>
          <ISOAbbreviation>Can J Neurol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cholinergic Neurons in Nucleus Subputaminalis in Primary Progressive Aphasia.</ArticleTitle>
        <Pagination>
          <StartPage>174</StartPage>
          <EndPage>183</EndPage>
          <MedlinePgn>174-183</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1017/cjn.2019.6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Primary Progressive Aphasia (PPA) is a syndrome characterized by an isolated impairment of language function at disease onset. The cholinergic system is implicated in language function and cholinergic deficits are seen in the brains of individuals with PPA. One major source of cholinergic innervation of the cerebral cortex is the nucleus basalis of Meynert (NBM) within which lies the nucleus subputaminalis (NSP). This nucleus is postulated to be involved in language function. We compared the abundance of cholinergic neurons in the NBM and NSP of controls and individuals with PPA. Also explored was whether the individuals presenting with PPA, who subsequently developed different clinical and neuropathological profiles, showed similar cholinergic deficits in the NSP.</AbstractText>
          <AbstractText Label="METHODS">Cytoarchitecture of the basal forebrain was studied using Nissl staining in control (n = 5) and PPA (n = 5) brains. Choline acetyltransferase (ChAT) immunohistochemical staining labeled cholinergic neurons were quantified using Neurolucida software.</AbstractText>
          <AbstractText Label="RESULTS">In comparison to matched controls, PPA showed reduction of cholinergic neurons in the NBM (t(8) = 4.04, p = 0.0037; Cohen's effect size value d = 2.62) and the NSP (t(6) = 4.62, p = 0.0042; Cohen's d effect size d = 2.92). The average percent of cholinergic neuronal loss was relatively higher in the NSP (64.7%) compared to the NBM (47.7%).</AbstractText>
          <AbstractText Label="CONCLUSION">Regardless of underlying pathology, all cases presenting with PPA showed a marked loss of cholinergic neurons in the NSP, providing further evidence for the importance of this nucleus in language function.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hamodat</LastName>
            <ForeName>Hayam</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Neuroscience,Dalhousie University,Halifax, Nova Scotia,Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fisk</LastName>
            <ForeName>John D</ForeName>
            <Initials>JD</Initials>
            <AffiliationInfo>
              <Affiliation>Nova Scotia Health Authority,Halifax,Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Darvesh</LastName>
            <ForeName>Sultan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Neuroscience,Dalhousie University,Halifax, Nova Scotia,Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>03</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Can J Neurol Sci</MedlineTA>
        <NlmUniqueID>0415227</NlmUniqueID>
        <ISSNLinking>0317-1671</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018888" MajorTopicYN="N">Aphasia, Primary Progressive</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020532" MajorTopicYN="N">Basal Nucleus of Meynert</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059329" MajorTopicYN="N">Cholinergic Neurons</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Alzheimer’s disease</Keyword>
        <Keyword MajorTopicYN="Y">Basal forebrain</Keyword>
        <Keyword MajorTopicYN="Y">Choline acetyltransferase</Keyword>
        <Keyword MajorTopicYN="Y">Nucleus of Ayala</Keyword>
        <Keyword MajorTopicYN="Y">Pick’s disease</Keyword>
        <Keyword MajorTopicYN="Y">Progressive supranuclear palsy</Keyword>
        <Keyword MajorTopicYN="Y">Vascular dementia</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30819267</ArticleId>
        <ArticleId IdType="doi">10.1017/cjn.2019.6</ArticleId>
        <ArticleId IdType="pii">S0317167119000064</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
